This change will take effect March 16, 2015
Overview and Clinical Utility
Effective March 16, 2015, PathGroup will change Group B Streptococcus (GBS) detection by routine culture to the FDA-approved BD MAX™ GBS assay, test code MGBS. The BD MAX™ GBS assay provides excellent clinical sensitivity and specificity, 95% and 96.7% respectively. PCR assays greatly increase sensitivity compared to the standard culture method for GBS screening.
Click Here to read more.